Michael Cookson, MD
Urology · Oklahoma City, OKNPI 1528142635
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $91,688 of the $132,047 with a category attached, or 69.4%. It is spread thinly across 23 manufacturers, the largest accounting for just 23.7%. Reporting peaked in 2019 at $43,594 and has fallen 89.1% since, to $4,730 in 2025. Among urology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $910.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$31K
- Astellas Pharma US Inc$30K
- Pfizer$15K
- Merck$15K
- Progenics Pharmaceuticals, Inc.$12K
- Ferring Pharmaceuticals Inc.$7K
- plus $22K from 17 others
Across 103 payments — averaging $5105.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medivation LLC.$422K
- Bayer$57K
- Pfizer$30K
- KARL Storz Endoscopy-america$17K
What the payments were for
- Consulting fees$91,68869%
- Speaking & faculty fees$24,81819%
- Travel & lodging$11,9199%
- Food & beverage$3,2402%
- Education$3820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 46 | $31,308 |
| Astellas Pharma US Inc | 20 | $30,252 |
| Pfizer | 9 | $15,182 |
| Merck | 7 | $15,083 |
| Progenics Pharmaceuticals, Inc. | 12 | $11,531 |
| Ferring Pharmaceuticals Inc. | 5 | $6,958 |
| Janssen Scientific Affairs, LLC | 7 | $6,567 |
| Johnson & Johnson | 14 | $5,456 |
| Myovant Sciences Inc. | 2 | $4,600 |
| Janssen Global Services, LLC | 2 | $2,568 |
| Provepharm Inc. | 1 | $1,000 |
| Urogen Pharma, Inc. | 4 | $868 |
| AstraZeneca | 5 | $191 |
| Sumitomo Pharma America, Inc. | 1 | $125 |
| Dendreon Pharmaceuticals LLC | 1 | $99 |
| Bluewind Medical | 1 | $67 |
| Novartis | 2 | $54 |
| Immunitybio, Inc. | 1 | $31 |
| Procept Biorobotics Corporation | 1 | $30 |
| Tolmar, Inc. | 1 | $23 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $17 |
| Telix Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$132,047 in reported general payments places this provider in the 95th percentile of 145 urology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 155 | $2,096,459 |
| ErleadaApalutamide | 16 | $236,928 |
| NubeqaDarolutamide | 16 | $179,907 |
| OrgovyxRelugolix | 64 | $160,450 |
| Abiraterone Acetate | 27 | $5,781 |
| Tamsulosin Hcl | 175 | $3,030 |
| Dutasteride | 72 | $1,740 |
| Finasteride | 66 | $1,307 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 51 | $1,172 |
| NitrofurantoinNitrofurantoin Macrocrystal | 21 | $479 |
| Imipramine Hcl | 27 | $418 |
| Prednisone | 19 | $151 |
| Solifenacin Succinate | 11 | $149 |
| Ciprofloxacin Hcl | 13 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $30,252 | $2,096,459155 claims |
| Johnson & JohnsonErleada | $5,456 | $236,92816 claims |
| BayerNubeqa | $31,308 | $179,90716 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $125 | $160,45064 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $6,567 | $5,78127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 145 urology providers in Oklahoma.
Other urology in Oklahoma City
- Mohammad RamadanOklahoma City$207K
- Kelly StrattonOklahoma City$62K
- Ashley BowenOklahoma City$32K
- Sardar Mohammad Khan GalzieOklahoma City$25K
- Basel HassounOklahoma City$20K
- Johnny HicksonOklahoma City$16K
- Michael HolzerOklahoma City$15K
- Dominic FrimbergerOklahoma City$12K
- Aaron BenhamOklahoma City$11K
- Kathryn CunninghamOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.